News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
491,842 Results
Type
Article (22900)
Company Profile (115)
Press Release (468827)
Section
Business (148103)
Career Advice (778)
Deals (27190)
Drug Delivery (87)
Drug Development (60089)
Employer Resources (84)
FDA (13903)
Job Trends (10533)
News (255173)
Policy (24823)
Tag
Academia (1225)
Alliances (39209)
Alzheimer's disease (792)
Approvals (13892)
Artificial intelligence (110)
Bankruptcy (213)
Best Places to Work (8478)
Biosimilars (83)
Breast cancer (124)
Cancer (1070)
Career advice (668)
CAR-T (90)
Cell therapy (274)
Clinical research (49136)
Collaboration (444)
Compensation (148)
COVID-19 (1752)
C-suite (101)
Data (1157)
Diabetes (156)
Diagnostics (4426)
Earnings (60819)
Events (69816)
Executive appointments (349)
FDA (14551)
Funding (337)
Gene therapy (177)
GLP-1 (470)
Government (3059)
Healthcare (11429)
Infectious disease (1819)
Inflammatory bowel disease (86)
Interviews (101)
IPO (12240)
Job creations (2395)
Job search strategy (597)
Layoffs (293)
Legal (4900)
Lung cancer (168)
Lymphoma (81)
Manufacturing (231)
Medical device (10833)
Medtech (10837)
Mergers & acquisitions (15208)
Metabolic disorders (363)
Neuroscience (1028)
NextGen: Class of 2025 (3852)
Non-profit (1493)
Northern California (1369)
Obesity (203)
Opinion (143)
Patents (108)
People (39675)
Phase I (15069)
Phase II (21377)
Phase III (16933)
Pipeline (536)
Postmarket research (1602)
Preclinical (5826)
Radiopharmaceuticals (185)
Rare diseases (185)
Real estate (4376)
Regulatory (18131)
Research institute (1172)
Resumes & cover letters (93)
Southern California (1196)
Startups (2529)
United States (12033)
Vaccines (391)
Weight loss (139)
Date
Last 7 days (522)
Last 30 days (1444)
Last 365 days (26302)
2025 (1165)
2024 (26702)
2023 (30914)
2022 (41087)
2021 (43908)
2020 (41696)
2019 (32760)
2018 (25073)
2017 (26049)
2016 (23972)
2015 (28430)
2014 (20600)
2013 (17151)
2012 (18752)
2011 (19536)
2010 (17102)
Location
Africa (445)
Arizona (93)
Asia (36132)
Australia (5071)
California (3071)
Canada (1129)
China (370)
Colorado (132)
Connecticut (140)
Europe (66192)
Florida (420)
Georgia (113)
Illinois (279)
Indiana (192)
Japan (85)
Kansas (78)
Maryland (548)
Massachusetts (2210)
Michigan (175)
Minnesota (196)
New Jersey (995)
New York (893)
North Carolina (579)
Northern California (1369)
Ohio (118)
Pennsylvania (737)
South America (803)
Southern California (1196)
Texas (414)
Washington State (307)
491,842 Results for "china biologic products".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
China
The Rise of China Innovation in the Time of Trump
With incoming president Donald Trump threatening a trade war with China, experts told
BioSpace
that the new administration will likely understand why medicines should be treated differently.
January 16, 2025
·
4 min read
·
Annalee Armstrong
China
Big Pharma Rushes to China for Deal Prospecting Despite Regulatory Uncertainty
China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.
January 7, 2025
·
6 min read
·
Annalee Armstrong
VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China
VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, announced that the Biologics License Application for Lonapegsomatropin was accepted by the China National Medical Products Administration.
March 7, 2024
·
2 min read
Antibody drug conjugate
Roche Kicks Off 2025 Committing a Potential $1B for Another ADC From China
Roche has once again returned to China to bolster its antibody-drug conjugate pipeline, this time striking a licensing deal with Innovent for $1 billion in biobucks.
January 2, 2025
·
2 min read
·
Annalee Armstrong
Press Releases
Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
January 6, 2025
·
6 min read
InnoCare Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China
InnoCare Pharma announced today that China National Medical Products Administration (NMPA) has accepted and granted priority review to a biologics license application (BLA) for tafasitamab in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
June 20, 2024
·
4 min read
Press Releases
Opening of Biosynth Biological Technology; a new Cutting-Edge Facility at Lifebay in Suzhou, China
October 30, 2024
·
2 min read
Press Releases
China’s National Medical Products Administration (NMPA) Approves PADCEV™ in combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Bladder Cancer
January 8, 2025
·
13 min read
Press Releases
Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China’s National Medical Products Administration
December 20, 2024
·
7 min read
ADCs
GSK Turns Back to China in Another Potential $1B+ ADC Deal
One year after a potential $1.7 billion deal with Hansoh Pharma, GSK goes back to China to forge another alliance with DualityBio for another deal that could be worth up to $1 billion as it continues to build up its ADC portfolio.
December 4, 2024
·
1 min read
·
Kate Goodwin
1 of 49,185
Next
